Registration holders in the EAEU must appoint a QPPV. Which powers to grant and what the inspector will check


The registration holder must appoint a Qualified Person for Pharmacovigilance (QPPV) and have that person permanently at its disposal. This requirement is set out in the Good Pharmacovigilance Practice (GVP) Rules of the Eurasian Economic Union (EAEU), hereinafter the GVP Rules. The GVP Rules were approved by Decision of the Council of the Eurasian Economic Commission (EEC) No. 87 of 3 November 2016. The QPPV is responsible for establishing and operating the registration holder’s pharmacovigilance system. A natural person performs the QPPV role. This person resides and works in one of the EAEU member states.

Where to look for the QPPV in Russian regulation

Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (hereinafter 61-FZ) places the pharmacovigilance obligations on registration holders. Under 61-FZ, registration holders must receive, record, process, analyze and retain reports from participants in the circulation of medicines and from public authorities on side effects; adverse reactions, including serious and unexpected ones; features of the interaction of medicinal products with other medicinal products; individual intolerance; and other facts and circumstances that threaten the life or health of a person or animal or affect the balance between the expected benefit and the possible risk of using the products. When registration holders identify information on serious and unexpected adverse reactions, on features of the interaction of medicinal products with other medicinal products, on individual intolerance, or on other facts and circumstances that affect the balance between the expected benefit and the possible risk, they must take measures to eliminate the negative consequences of using such products, prevent harm to the life or health of a person or animal, protect against the use of such products, and collect additional data on their efficacy and safety. These obligations also apply to legal entities in whose names clinical trial authorizations have been issued, and to other legal entities authorized by registration holders or by those legal entities.
Participants in the circulation of medicines must report to the authorized federal executive body, in particular, side effects and adverse reactions from the use of medicinal products, and other facts and circumstances that threaten the life or health of a person or animal. Under the legislation of the Russian Federation, liability for failing to report or concealing this information rests with registration holders, with legal entities in whose names clinical trial authorizations have been issued and other legal entities authorized by them, and with officials who learned of the information in the course of their professional activities. On receiving evidence that a medicinal product does not meet the established requirements, or information that its efficacy and safety data do not match the data in the package leaflet (including information identified by the regulatory and supervisory authorities of foreign states), the authorized federal executive body considers suspending the use of the product. 61-FZ does not contain the term «Qualified Person for Pharmacovigilance».
The Procedure for Pharmacovigilance of Medicinal Products for Medical Use was approved by Order of the Federal Service for Surveillance in Healthcare (Roszdravnadzor) No. 3518 of 17 June 2024 (hereinafter Order No. 3518; the procedure it approves is hereinafter Procedure No. 3518). Order No. 3518 entered into force on 1 March 2025 and remains in effect until 1 March 2031. It repealed Roszdravnadzor Orders No. 1071 of 15 February 2017 and No. 6252 of 16 July 2020. Procedure No. 3518 mentions neither the QPPV nor the registration holder’s pharmacovigilance contact person. It mentions an official responsible for pharmacovigilance only for medical organizations. The registration holder’s pharmacovigilance system must comply with the GVP Rules. The main requirements for the QPPV are set out in the GVP Rules.
The GVP Rules define the pharmacovigilance system master file (PSMF) as a detailed description of the pharmacovigilance system used by the registration holder. 61-FZ defines the risk management plan (RMP) as a detailed description of pharmacovigilance measures aimed at identifying, assessing and preventing or minimizing risks associated with medicinal products. Under 61-FZ, the Russian Ministry of Health provides the PSMF and the RMP to Roszdravnadzor on its request, for the purposes of state control (supervision) in the sphere of the circulation of medicines. The procedure for providing them was approved by Order of the Russian Ministry of Health No. 672n and of Roszdravnadzor No. 6915 of 6 December 2024. If the information includes data constituting a trade secret, the Russian Ministry of Health sends the registration holder a notice of its provision, stating the scope, to the address given in the application for state registration of the product. The QPPV is responsible for the PSMF.

What the GVP Rules require of the QPPV

Each pharmacovigilance system may have only one QPPV. Several registration holders may use the services of one QPPV, and one person may perform the QPPV functions for several systems of the same registration holder, provided that the person is able to carry out all the duties. A registration holder may set up several systems, for example for vaccines or non-prescription medicinal products, and each system is described in a separate PSMF.

Table 1. Requirements of the GVP Rules for the QPPV

RequirementWhat to check in your organization
A natural person in the QPPV roleThe appointment order and the PSMF name a specific person by surname, first name and patronymic
Residence and work in an EAEU member stateThe country of residence is stated in the summary of the pharmacovigilance system that the registration holder submits with subsequent registration applications, and the work address is stated in the PSMF
Job description and place in the structureThe duties are set out in the job description, the QPPV’s position is defined in the organizational structure at the level of the registration holder’s management personnel, and information about the QPPV is included in the PSMF
Qualifications and trainingThe level of training is stated in the job description, and training on the registration holder’s system was completed and documented before the person took up the role
Cover during absenceA backup procedure names a deputy, who can be reached at the QPPV’s contact details
Access of the authorized body to the QPPVThe QPPV ensures round-the-clock (24-hour) access of the authorized body to themselves
Access of the QPPV to the adverse reaction databaseThe QPPV can obtain information from the database at any time when an immediate response to an urgent request of the authorized body is needed, including outside working hours
Copy of the PSMF on requestA copy of the master file is provided within 7 working days after the request is received

The registration holder gives the QPPV sufficient powers to manage pharmacovigilance activities and the quality system, access to the PSMF, and information on any changes to it. These powers must allow the QPPV to make changes to the system, to risk management plans and to the preparation of regulatory action in response to an emerging safety issue (an issue that the registration holder has assessed as requiring urgent attention of the authorized body because of its potentially significant effect on the benefit-risk balance of the product or on public health, and because of the potential need for immediate regulatory action and for informing patients and healthcare professionals). The QPPV receives from senior management information on the results of quality system reviews and the measures taken, compliance data and information on planned audits, and may initiate an audit when necessary. After each audit that is significant for the pharmacovigilance system, senior management provides the QPPV with a copy of the corrective and preventive action (CAPA) plan. The QPPV confirms the agreement of the RMP by signature or other evidence of approval. The QPPV takes part in assessing and approving the protocols of post-registration safety studies.
The registration holder ensures that the QPPV is informed of any intention to acquire another company or individual medicinal products of another holder. The QPPV assesses the effect of the new products on the existing system, ensures that the system is adapted, and determines which data the previous holder must transfer and by when. The registration holder informs the QPPV of the parties’ contractual obligations on pharmacovigilance and the exchange of safety data and gives the QPPV the right to make changes to that part of the obligations. If the registration holder intends to cooperate with another holder, organization or natural person who could directly or indirectly affect the system, it informs the QPPV before the contractual arrangements are concluded, in time to assess the effect of that cooperation on the system. The QPPV may make proposals and changes concerning the contractual obligations that relate to the system.
The QPPV must have theoretical knowledge and practical experience in pharmacovigilance, skills in managing pharmacovigilance systems, and skills in conducting expert assessment, or access to it, in areas such as medicine, pharmaceutical sciences, epidemiology and biostatistics. The registration holder sets the level of training of the QPPV in the job description. In describing the QPPV’s qualifications, the GVP Rules do not name a specific degree or specialty. Among the powers that the registration holder gives the QPPV under the GVP Rules, there is no right to suspend the circulation of a medicinal product independently. When safety issues are identified, the QPPV must assist in preparing regulatory measures.
The QPPV may delegate individual tasks to persons with appropriate qualifications and training, provided that the QPPV oversees the functioning of the whole system and the safety profiles of all medicinal products and that such delegation is documented. A registration holder may delegate all or part of its pharmacovigilance tasks, including the QPPV functions, to another organization or person if the same requirements as for an organization can be applied to that person; responsibility for performing the tasks remains with the registration holder. The data on the QPPV in the PSMF may be the data of a person who works under a contract and is not on the registration holder’s staff. The requirement to reside and work in an EAEU member state applies to any person authorized to perform the QPPV functions. The delegation agreement must contain a detailed description of the delegated tasks, the way of interaction and data exchange, time commitments and monitoring of the activities performed. The registration holder should regularly audit the organizations to which tasks are delegated.

How the QPPV differs from the pharmacovigilance contact person

The GVP Rules allow authorized bodies to require the appointment of a pharmacovigilance contact person (PV contact person). The PV contact person is accountable to the QPPV for tasks and duties, but accountability does not necessarily mean direct subordination. The PV contact person may perform the QPPV functions.

Table 2. Differences between the QPPV and the PV contact person

ParameterQPPVPV contact person
BasisGVP Rules; the registration holder must appointGVP Rules; appointed at the request of the authorized body
ResponsibilityFor establishing and operating the systemAccountable to the QPPV for tasks and duties
Post-registration safety studiesThe QPPV takes part in assessing and approving the protocolsThe PV contact person at the level of an EAEU member state must be informed of a post-registration safety study that the registration holder conducts or sponsors in the territory of that state, and must have access to the protocol
Information in the dossier and the PSMFThe QPPV’s CV, qualifications and contact details in the PSMF; contact details in the summary of the pharmacovigilance systemThe PV contact person’s contact details in the summary of the pharmacovigilance system; the area of responsibility in the PSMF

The Rules for Registration and Regulatory Review of Medicines for Medical Use were approved by Decision of the EEC Council No. 78 of 3 November 2016 (as amended on 26 November 2025; hereinafter the Registration and Review Rules). When a registration holder first applies for registration of a product on the EAEU market, it submits the PSMF. For subsequent applications, a summary of the pharmacovigilance system is submitted. Among other things, the summary includes confirmation that a QPPV is in place; if the registration holder is not located in the territory of an EAEU member state, confirmation that a PV contact person is in place in the territory of an EAEU member state is also required.
The registration application form under the Registration and Review Rules requires the following details of the QPPV: surname, first name and patronymic, country, round-the-clock telephone and fax numbers, e-mail address, place of registration and actual place of residence, and also the PSMF number and the address where it is located. The form contains separate details of a person who differs from the QPPV. The heading of this section of the form calls that person the registration holder’s authorized person in an EAEU member state for pharmacovigilance, and the hint to the section calls that person the pharmacovigilance contact person.

How to notify the appointment or replacement of the QPPV

The registration holder notifies the authorized bodies of the EAEU member states of the QPPV’s surname and contact information. If the QPPV’s surname or contact information changes, the registration holder must inform the authorized bodies of the EAEU member states without delay, within 30 calendar days. When the QPPV is replaced or the QPPV’s contact information changes, and also when the location of the PSMF changes, the registration holder submits an application for variation to the authorized bodies.
Under the Registration and Review Rules, the introduction of a summary of the pharmacovigilance system, a change of the QPPV (including contact information) and a change of the PSMF location are classified as changes under code V.I.8 (the letter V transliterates the Cyrillic letter used in the Rules). For these changes the procedure for a minor Type IA variation with immediate notification is set: the application for variation is submitted immediately, within 20 working days from the date the change is implemented.
An application for a change under V.I.8 is accompanied by the summary of the pharmacovigilance system or an update of its significant elements (as the case may be), and also the PSMF number, if there is one. The significant elements of the summary are: confirmation that the applicant has a QPPV and the applicant’s signed statement that the QPPV has the necessary means to perform the tasks and duties under the GVP Rules; contact information of the QPPV, stating the country where the QPPV is located and performs the tasks; and the location of the PSMF.

Which deadlines apply to the pharmacovigilance system

Table 3. Deadlines in the pharmacovigilance system

SituationDeadlineBasis
Information that falls within the definition of an emerging safety issue3 working days, to the e-mail address ESI@roszdravnadzor.gov.ru, with a mandatory paper copy to followProcedure No. 3518; GVP Rules
Analysis of the reliability of information on new safety data10 working days from receipt of the Roszdravnadzor noticeProcedure No. 3518
Periodic safety update report (PSUR) brought into line with the comments of the expert organization (a federal state budgetary institution subordinate to Roszdravnadzor)30 working days from receipt of the Roszdravnadzor electronic notice of rejection of the PSURProcedure No. 3518
RMP60 working days from receipt of the Roszdravnadzor requestProcedure No. 3518
RMP with the changes made30 working days from receipt of the notice that changes are neededProcedure No. 3518
Copy of the PSMF7 working days from receipt of the request of the authorized bodyGVP Rules

The 3-working-day deadline for an emerging safety issue runs from the moment it is established that a validated signal or safety issue meets the definition of an emerging safety issue.

How the QPPV is inspected and which measures are provided for

The scope of a scheduled inspection depends on its type. The elements of the system named for assessment include the roles and duties of the QPPV: access to the quality system, the PSMF, performance measures and system indicators, audit and inspection reports, and the ability to take measures to improve the system’s compliance with the requirements. In an unscheduled inspection, the aspects assessed may include the QPPV’s involvement in and awareness of issues concerning a specific medicinal product.
The authorized body takes a replacement of the QPPV after the last inspection into account among the factors when drawing up the inspection plan and determining the scope of a repeat inspection.
The grounds for an unscheduled inspection include, in particular, a delay or failure to meet the obligations to submit information on safety issues, a refusal to submit the requested information within the time limits set by the authorized bodies, and a delay in implementing, or improper performance of, corrective and preventive actions following previous inspections.
Pre-registration inspections are not mandatory. When deciding whether to order a pre-registration inspection, account is taken, in particular, of the fact that the applicant has not previously worked with the existing pharmacovigilance system in the territories of EAEU member states or is creating a new one. If, following a pre-registration inspection, concerns arise about the ability of the registration holder to meet the requirements for the pharmacovigilance system, the possible measures include refusal of registration, of confirmation of registration (re-registration), or of other registration-related procedures, and other measures.
If a registration holder fails to comply with its pharmacovigilance obligations, the possible measures include, in particular, a warning letter, a statement of non-compliance or a notice of violation, and consideration of publishing a list of holders that seriously or persistently breach the requirements. The actions concerning the registration certificate that are named include, for example, suspension or cancellation of the registration certificate and suspension of the review of new registration applications until corrective and preventive actions are implemented.
Procedure No. 3518 provides, in particular, for the following actions of Roszdravnadzor on the conclusions of the expert organization:
1. The expert organization informs Roszdravnadzor, within 5 working days from the date of the expert opinion, of three consecutive failures of the PSUR for one product to meet the requirements of Section VIII of the GVP Rules. Roszdravnadzor decides whether an unscheduled inspection of the registration holder’s pharmacovigilance system for that product is necessary.
2. When the expert organization finds that a participant in the circulation of medicines has not complied with the mandatory pharmacovigilance requirements, Roszdravnadzor decides whether it is necessary to suspend the use of the product and conduct an unscheduled inspection of the registration holder’s pharmacovigilance system.
3. Within 5 working days from receipt of the conclusion of the expert organization, Roszdravnadzor sends the Russian Ministry of Health information for suspending the registration certificate or restricting the use of the product. The information is sent if the conclusion contains one of the following findings:
a) the product is dangerous: it causes serious or irreparable harm to human health, or an unfavorable benefit-risk balance has been proven, or documented insufficient therapeutic efficacy has been identified when the conditions of use described in the Summary of Product Characteristics (SmPC) are observed;
b) the registration holder’s pharmacovigilance obligations have not been fulfilled;
c) the requirements of the authorized body set at registration under the Registration and Review Rules have not been fulfilled, if such requirements were set.
4. If the registration holder’s materials on additional risk minimization measures fail to comply three times in a row, Roszdravnadzor decides whether it is necessary to suspend the use of the product and conduct an unscheduled inspection of the registration holder’s pharmacovigilance system.

The Code of the Russian Federation on Administrative Offenses (hereinafter the Administrative Offenses Code, as amended on 4 August 2026) establishes liability for failure to submit, or late submission of, information to the federal executive body that exercises control and supervision functions in healthcare, or to its territorial body, where submission is mandatory under the legislation on the protection of health, and for submitting knowingly inaccurate information. This provision does not apply to certain cases covered by the article of the Administrative Offenses Code on failure to fulfill the obligations to provide information on a conflict of interest in medical and pharmaceutical activity. The fine is 10,000-15,000 Russian rubles (RUB) for officials and RUB 30,000-70,000 for legal entities. This provision of the Administrative Offenses Code does not name reports on adverse reactions or safety reports.

What to do

Cross-check the details of the QPPV. Compare the surname, first name, patronymic, country of residence, work address and contact information in the appointment order, the job description, the summary of the pharmacovigilance system and the PSMF. If the details have changed, submit an application for the change under V.I.8 within 20 working days from the date the change is implemented and inform the authorized bodies within 30 calendar days. The first deadline is set by the Registration and Review Rules and the second by the GVP Rules, so count each separately.
Set out the powers in the job description. Include access to the PSMF and the adverse reaction database, the right to make changes to the system and the RMP, the right to initiate an audit, receipt of copies of CAPA plans, participation in assessing the protocols of post-registration safety studies, and being informed of transactions and contracts before they are concluded.
Check cover and round-the-clock contact. Name a deputy, document the backup procedure and make sure that, when the QPPV is temporarily absent, the deputy can be reached at the QPPV’s contact details and the round-the-clock access of the authorized body to the QPPV is in place. Check this by calling on a day off.
Fix the procedure for an emerging safety issue. In a standard operating procedure, name who decides, and within what time limit, that an issue is an emerging safety issue, who sends the information to the e-mail address given in Procedure No. 3518, and who sends the paper copy. The deadline is 3 working days.
Collect the documents for the inspection. Prepare a copy of the PSMF so that it can be submitted within 7 working days after the request, the audit plan, the audit reports and the CAPA plans. If the QPPV functions have been transferred to a contractor, check the contract and the contractor’s audit schedule. Prepare the QPPV for questions on one specific medicinal product.


Regulatory framework:

1. Decision of the Council of the Eurasian Economic Commission No. 87 of 3 November 2016 «On Approval of the Good Pharmacovigilance Practice Rules of the Eurasian Economic Union» (as amended on 19 May 2022)
2. Decision of the Council of the Eurasian Economic Commission No. 78 of 3 November 2016 «On the Rules for Registration and Regulatory Review of Medicines for Medical Use» (as amended on 26 November 2025)
3. Order of the Federal Service for Surveillance in Healthcare No. 3518 of 17 June 2024 «On Approval of the Procedure for Pharmacovigilance of Medicinal Products for Medical Use» (registered with the Russian Ministry of Justice on 5 September 2024, No. 79394)
4. Order of the Russian Ministry of Health No. 672n and of the Federal Service for Surveillance in Healthcare No. 6915 of 6 December 2024 «On Approval of the Procedure for Interagency Information Exchange on the Provision by the Ministry of Health of the Russian Federation to the Federal Service for Surveillance in Healthcare of Information on Medicines, Including Where Such Information Constitutes a Trade Secret, Specified in Part 2.1 of Article 9 of Federal Law No. 61-FZ of 12 April 2010 ‘On the Circulation of Medicines’» (registered with the Russian Ministry of Justice on 12 February 2025, No. 81222)
5. Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (as amended on 4 August 2026, applicable from 1 September 2026)
6. Code of the Russian Federation on Administrative Offenses No. 195-FZ of 30 December 2001 (as amended on 4 August 2026)
7. Order of the Federal Service for Surveillance in Healthcare No. 1071 of 15 February 2017 «On Approval of the Procedure for Carrying Out Pharmacovigilance» and Order No. 6252 of 16 July 2020 «On Amendments to the Procedure for Carrying Out Pharmacovigilance Approved by Order No. 1071 of the Federal Service for Surveillance in Healthcare of 15 February 2017» (repealed by Order No. 3518): mentioned as repealed

This page in Russian→